Expert Interviews

Medical experts specializing in hepatocellular carcinoma (HCC) provide a detailed analysis of the IMbrave 150 study design.

It can be hard to get exposure for a new field, but Jessica Cheng, MD, has big plans on how to advance the field of cancer rehabilitation.

Surbhi Sidana, MD, discussed LINKER-MM1 trial efficacy findings, in which linvoseltamab was evaluated in patients with relapsed/refractory multiple myeloma.

Anyone undergoing cancer treatments could benefit from cancer rehabilitation, according to Jessica Cheng, MD.

Surbhi Sidana, MD, discussed outpatient supportive care for patients following immunotherapy treatment for hematologic cancers.

Jessica Cheng, MD, noted that working with patients in the field of cancer rehabilitation to improve recovery times brings her joy.

Jorge Cortes, MD, provides clinical insights on the utilization of TKIs in CML and outlines associated adverse events.

The Oncology Brothers and Jorge Cortes, MD, discuss treatment practices for patients with accelerated phase chronic myeloid leukemia.

An expert on chronic myeloid leukemia provides clinical insights on treatment practices following progression.

A hematologist-oncologist and the Oncology Brothers outline treatment paradigms for chronic phase CML and discuss patient monitoring practices.

Jorge Cortes, MD, joins Rahul Gosain, MD, and Rohit Gosain, MD, to discuss patient workup and risk stratification practices in chronic myeloid leukemia (CML).

Claire Saxton shares insights on how physicians and caregivers can best assist patients with CML who have switched therapies.

A panel of experts on chronic myeloid leukemia discuss common patient concerns, adverse effect considerations, and best practices for setting clear expectations.

Experts give an overview of long-term follow-up efficacy data from the MonumenTAL-1 study.

Medical experts give an overview of relapsed/refractory multiple myeloma, focusing on diagnosis and current management strategies

Medical oncologists discuss the overall research landscape in advanced EGFR-mutant NSCLC, highlighting exciting trials and emerging data in the evolving treatment space.

Martin Dietrich, MD, PhD, shares expert perspectives on recent data from TROPION-Lung05 and HERTHENA-Lung01 in advanced EGFR-mutant NSCLC.

Wade T. Iams, MD, provides clinical insights on proactive management strategies for patients receiving amivantamab for advanced EGFR-mutant NSCLC.

Focusing on treatment practices for patients with advanced EGFR-mutant NSCLC, Martin Dietrich, MD, PhD, discusses how the availability of subcutaneous amivantamab can potentially address current treatment barriers.

Wade T. Iams, MD, outlines insights gleaned from recently presented data from the PALOMA-3 trial in advanced EGFR-mutant non–small cell lung cancer.